These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29572505)

  • 1. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Rule S; Jurczak W; Jerkeman M; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Thieblemont C; Zhou W; Henninger T; Goldberg J; Vermeulen J; Dreyling M
    Leukemia; 2018 Aug; 32(8):1799-1803. PubMed ID: 29572505
    [No Abstract]   [Full Text] [Related]  

  • 2. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
    Hess G; Rule S; Jurczak W; Jerkeman M; Santucci Silva R; Rusconi C; Caballero D; Joao C; Witzens-Harig M; Bence-Bruckler I; Cho SG; Zhou W; Goldberg JD; Trambitas C; Enny C; Vermeulen J; Traina S; Chiou CF; Diels J; Dreyling M
    Leuk Lymphoma; 2017 Dec; 58(12):2824-2832. PubMed ID: 28556689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ready, AIM, stop: ibrutinib plus venetoclax in MCL.
    Wallace DS; Barr PM
    Blood; 2024 Aug; 144(8):800-802. PubMed ID: 39172439
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Jurczak W; Ramanathan S; Giri P; Romano A; Mocikova H; Clancy J; Lechuga M; Casey M; Boni J; Giza A; Hess G
    Leuk Lymphoma; 2018 Mar; 59(3):670-678. PubMed ID: 28768446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
    Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
    Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Martin P; Bartlett NL; Blum KA; Park S; Maddocks K; Ruan J; Ridling L; Dittus C; Chen Z; Huang X; Inghirami G; DiLiberto M; Chen-Kiang S; Leonard JP
    Blood; 2019 Mar; 133(11):1201-1204. PubMed ID: 30692121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
    Tobinai K; Uchida T; Fukuhara N; Nishikawa T
    Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
    [No Abstract]   [Full Text] [Related]  

  • 10. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
    Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
    Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
    Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Hernández-Rivas JÁ; Qi K; Deshpande S; Parisi L; Wang M
    Haematologica; 2019 May; 104(5):e211-e214. PubMed ID: 30442728
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
    Freeman CL; Pararajalingam P; Jin L; Balasubramanian S; Jiang A; Xu W; Grau M; Zapukhlyak M; Boyle M; Hodkinson B; Schaffer M; Enny C; Deshpande S; Sun S; Vermeulen J; Morin RD; Scott DW; Lenz G
    Leukemia; 2022 Oct; 36(10):2479-2487. PubMed ID: 35963941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
    Visco C; Di Rocco A; Evangelista A; Quaglia FM; Tisi MC; Morello L; Zilioli VR; Rusconi C; Hohaus S; Sciarra R; Re A; Tecchio C; Chiappella A; Marin-Niebla A; McCulloch R; Gini G; Perrone T; Nassi L; Pennese E; Stefani PM; Cox MC; Bozzoli V; Fabbri A; Polli V; Ferrero S; Celis MIA; Sica A; Petrucci L; Arcaini L; Rule S; Krampera M; Vitolo U; Balzarotti M
    Leukemia; 2021 Mar; 35(3):787-795. PubMed ID: 32782382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy.
    Leitinger EJ; Wright RM; Nelson N; Anderson MA; Juneja S
    Pathology; 2021 Dec; 53(7):926-929. PubMed ID: 33947523
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
    Srour SA; Lee HJ; Nomie K; Ye H; Chen W; Oriabure O; Romaguera J; Wang ML
    Br J Haematol; 2018 May; 181(4):561-564. PubMed ID: 28369820
    [No Abstract]   [Full Text] [Related]  

  • 18. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
    Wang ML; Jurczak W; Jerkeman M; Trotman J; Zinzani PL; Belada D; Boccomini C; Flinn IW; Giri P; Goy A; Hamlin PA; Hermine O; Hernández-Rivas JÁ; Hong X; Kim SJ; Lewis D; Mishima Y; Özcan M; Perini GF; Pocock C; Song Y; Spurgeon SE; Storring JM; Walewski J; Zhu J; Qin R; Henninger T; Deshpande S; Howes A; Le Gouill S; Dreyling M;
    N Engl J Med; 2022 Jun; 386(26):2482-2494. PubMed ID: 35657079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCL.
    Killock D
    Nat Rev Clin Oncol; 2024 Jul; 21(7):483. PubMed ID: 38789564
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
    Rai S; Tanizawa Y; Cai Z; Huang YJ; Taipale K; Tajimi M
    Adv Ther; 2022 Oct; 39(10):4792-4807. PubMed ID: 35984628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.